Published March 12, 2016 | Version v1
Journal article Open

A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson’s disease

  • 1. Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal
  • 2. Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
  • 3. The Cure Parkinson’s Trust, London, UK
  • 4. HSG-IMIT, Villingen-Schwenningen, Germany
  • 5. Norwegian Centre for Telemedicine, Tromso, Norway
  • 6. Hasomed GmbH, Magdeburg, Germany
  • 7. AbilityNet, London, UK
  • 8. Institute for Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany
  • 9. Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany

Description

Background: There is growing interest in having objective assessment of health-related outcomes using technology-based devices that provide unbiased measurements which can be used in clinical practice and scientific research. Many studies have investigated the clinical manifestations of Parkinson’s disease using such devices. However, clinimetric properties and clinical validation vary among the different devices.

Methods: Given such heterogeneity, we sought to perform a systematic review in order to (i) list, (ii) compare and (iii) classify technological-based devices used to measure motor function in individuals with Parkinson's disease into three groups, namely wearable, non-wearable and hybrid devices. A systematic literature search of the PubMed database resulted in the inclusion of 168 studies. These studies were grouped based on the type of device used. For each device we reviewed availability, use, reliability, validity, and sensitivity to change. The devices were then classified as (i) ‘recommended’, (ii) ‘suggested’ or (iii) ‘listed’ based on the following criteria: (1) used in the assessment of Parkinson’s disease (yes/no), (2) used in published studies by people other than the developers (yes/no), and (3) successful clinimetric testing (yes/no).

Results: Seventy-three devices were identified, 22 were wearable, 38 were non-wearable, and 13 were hybrid devices. In accordance with our classification method, 9 devices were ‘recommended’, 34 devices were ‘suggested’, and 30 devices were classified as ‘listed’. Within the wearable devices group, the Mobility Lab sensors from Ambulatory Parkinson’s Disease Monitoring (APDM), Physilog®, StepWatch 3, TriTrac RT3 Triaxial accelerometer, McRoberts DynaPort, and Axivity (AX3) were classified as ‘recommended’. Within the non-wearable devices group, the Nintendo Wii Balance Board and GAITRite® gait analysis system were classified as ‘recommended’. Within the hybrid devices group only the Kinesia® system was classified as ‘recommended’.

Files

12984_2016_Article_136.pdf

Files (837.6 kB)

Name Size Download all
md5:331755e0333b7847a412fda5ba83fb70
243.9 kB Download
md5:cd5e8bfb10abc3a96a98da0a58ecdce7
567.5 kB Preview Download
md5:eea738e1ed333a918cc9d83c020ceb7d
26.2 kB Download

Additional details

Funding

SENSE-PARK – SENSE-PARK: Supporting and Empowering Parkinson patients in their home environment using a Novel SEnsory information system that monitors daily-life-relevant parameters of PARKinson disease and their 288557
European Commission